iPS

Genomic instability in human pluripotent stem cells derivatives

by Alexey Bersenev on January 25, 2012 · 0 comments

in embryonic/iPS

Method of the year 2011 – Targeted genome editing by zinc finger nucleases

by Alexey Bersenev on January 2, 2012 · 0 comments

in methods

Moving forward to GMP-grade manufacturing of iPS cells

by Alexey Bersenev on December 16, 2011 · 0 comments

in cell product,embryonic/iPS

Ian Wilmut on the future of iPS cells, reprogramming and direct transdifferentiation

by Alexey Bersenev on December 5, 2011 · 0 comments

in direct reprogramming,embryonic/iPS

The pattern of genetic alterations in cultured human pluripotent stem cells

by Alexey Bersenev on November 29, 2011 · 0 comments

in embryonic/iPS

Lecture: Chris Parker – Human iPS cells in drug discovery and development

by Alexey Bersenev on November 1, 2011 · 0 comments

in embryonic/iPS,lectures

Methods and protocols digest: iPS cells – part 1

by Alexey Bersenev on October 16, 2011 · 0 comments

in embryonic/iPS,methods,protocols

Lecture: Tim Kamp – Human pluripotent stem cells: tools for cardiovascular medicine

by Alexey Bersenev on September 22, 2011 · 0 comments

in lectures

Yamanaka’s comment on immunogenicity of iPS cells – An update

by Alexey Bersenev on September 19, 2011 · 0 comments

in embryonic/iPS

Direct comparison of human pluripotent stem cell derivatives with tissue-derived counterparts

by Alexey Bersenev on September 12, 2011

in embryonic/iPS

← Previous Entries